Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023

Rhea-AI Summary

Amneal Pharmaceuticals (NYSE: AMRX) will announce its fourth quarter and full year 2022 financial results on March 2, 2023, before the market opens. A conference call and live webcast will take place at 8:30 a.m. Eastern Time on the same day. Investors can access the call via the Investor Relations section of the company's website here. To join the call, U.S. callers can dial 1 (844) 200-6205 and international callers 1 (929) 526-1599, using the access code 477511. A replay will be available for seven days following the call.

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2023.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.

To access the call through a conference line, dial 1 (844) 200-6205 (in the U.S.) or 1 (929) 526-1599 (international callers). The access code for the call is 477511.

A replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial 1 (866) 813-9403 (in the U.S.) or +44 (204) 525-0658 (international callers). The access code for the replay is 942331.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005199/en/

Anthony DiMeo

Head of Investor Relations

Anthony.DiMeo@amneal.com

Source: Amneal Pharmaceuticals, Inc.

FAQ

When will Amneal Pharmaceuticals release its Q4 2022 financial results?

Amneal Pharmaceuticals will release its fourth quarter and full year 2022 financial results on March 2, 2023.

What time is the Amneal Pharmaceuticals conference call?

The conference call for Amneal Pharmaceuticals will take place at 8:30 a.m. Eastern Time on March 2, 2023.

How can I access the Amneal Pharmaceuticals conference call?

You can access the Amneal Pharmaceuticals conference call by dialing 1 (844) 200-6205 for U.S. callers and 1 (929) 526-1599 for international callers, using access code 477511.

Is there a replay available for the Amneal Pharmaceuticals conference call?

Yes, a replay of the Amneal Pharmaceuticals conference call will be available for seven days after the call.

Where can I find Amneal Pharmaceuticals' financial results?

Amneal Pharmaceuticals' financial results will be available on the Investor Relations section of their website at https://investors.amneal.com.